Capsovision, Inc (CV) Stock Price & Analysis
Capsovision, Inc (CV) fell 2.54% to USD 7.3 as of June 10, 2026 at 14:58 UTC, according to Nexqual real-time market data.
CV last closed at USD 7.49; the session ranged USD 7.29–7.6 on volume of 38,274 shares. Market capitalization is $364.73M, with a 52-week range of USD 3.43–15.37 (NCM). Source: Nexqual, June 10, 2026 at 14:58 UTC.
Key Statistics (as of June 10, 2026 at 14:58 UTC)
| Price | USD 7.3 |
|---|---|
| Change | ▼ 2.54% (down) |
| Previous Close | USD 7.49 |
| Open | USD 7.6 |
| Day Range | USD 7.29 – 7.6 |
| 52-Week Range | USD 3.43 – 15.37 |
| Volume | 38,274 shares |
| Market Cap | $364.73M |
| Exchange | NCM |
Technical Analysis (CV)
Nexqual's technical model rates CV "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of June 10, 2026 at 14:58 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.63 (neutral) |
| vs SMA50 | Above (USD 6.69) |
| MACD | 0.16 (positive) |
Analyst Ratings (CV)
Wall Street analysts rate CV "None" based on 1 analysts, with a mean price target of USD 10 (range USD 10–10), per Nexqual as of June 10, 2026 at 14:58 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 10 |
| High Target | USD 10 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (CV)
| Next Earnings Date | 2026-08-13 |
|---|---|
| Revenue Estimate | $3.81M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.15 vs est -0.13 ▼ miss |
| 2025-12-31 | USD -0.16 vs est -0.15 ▼ miss |
| 2025-09-30 | USD -0.17 vs est -0.13 ▼ miss |
| 2025-06-30 | USD -0.1 vs est -0.11 ▲ beat |
Source: Nexqual, June 10, 2026 at 14:58 UTC.
Financials & Fundamentals (CV)
| Total Revenue | $13.56M |
|---|---|
| Revenue Growth (YoY) | +0.30% |
| Gross Margin | +51.67% |
| Operating Margin | -254.05% |
| Profit Margin | -198.87% |
| ROE | -185.09% |
| Debt / Equity | 3.9 |
| Current Ratio | 4.57 |
| Total Cash | $17.93M |
| Total Debt | $788,000 |
| Free Cash Flow | $-13.24M |
Source: Nexqual, June 10, 2026 at 14:58 UTC.
Financial Health Score (CV)
Nexqual rates Capsovision, Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 14:58 UTC.
| Growth | Mixed — Revenue +0.3% YoY (latest Q), slow |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $18M cash, no debt |
| Cash Flow | Weak — FCF negative: -$13M, burning cash |
| Efficiency | Critical — ROE -185%, ROA -88.1% |
Ownership (CV)
| Insider Ownership | +32.07% |
|---|---|
| Institutional Ownership | +8.12% |
| Shares Outstanding | 49.96M |
| Float | 31.58M |
| Short % of Float | +3.60% |
Source: Nexqual, June 10, 2026 at 14:58 UTC.
Leadership (CV)
Capsovision, Inc is led by Kang-Huai Wang (age 68), Co-Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 14:58 UTC.
| Co-Founder, President, CEO & Director | Kang-Huai Wang (age 68) |
|---|---|
| Senior Vice President of Global Sales | Douglas Atkinson (age 57) |
Major Backers & Investors (CV)
Notable institutional backers of Capsovision, Inc include Fidelity, UBS Group AG, Xtx Topco Ltd, according to Nexqual as of June 10, 2026 at 14:58 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.24% |
| UBS Group AG | 0.13% |
| Xtx Topco Ltd | 0.13% |
| Charles Schwab Investment Management, Inc. | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.6% |
| BlackRock | 4.33% |
| Geode Capital | 0.87% |
| State Street | 0.51% |
| Northern Trust | 0.3% |
Source: Nexqual, June 10, 2026 at 14:58 UTC.
From Capsovision, Inc's Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our CapsoCam Colon (subject to FDA clearance) incorporates our proprietary 3D-sensing technology to more accurately measure polyp sizes.
- For the years ended December 31, 2025 and 2024, we generated approximately $13.6 million and $11.8 million, respectively, in revenue from sales of CapsoCam Plus, an increase of approximately 15% over the prior year.
- Our CapsoCam Colon also incorporates our proprietary 3D-sensing technology to more accurately measure the size of polyps in the GI tract, enabling physicians to more confidently decide that patients with small (e.g., less than 6mm) polyps may forgo a follow-on colonoscopy, increasing the utility of the procedure for healthcare providers and patients alike.
- Building upon the commercial success and the existing design of our CapsoCam Plus capsule, we developed our next pipeline capsule endoscope, CapsoCam Colon.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CNL | Collective Mining Ltd. | USD 13.46 | ▼ 6.3% |
| EE | Excelerate Energy, Inc. | USD 32.79 | ▲ 2.97% |
| UTL | UNITIL Corporation | USD 52.32 | ▲ 3.34% |
| IDA | IDACORP, Inc. | USD 141.53 | ▲ 2.5% |
| POM | POMDOCTOR LIMITED | USD 0.11 | ▼ 0.27% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 14:58 UTC. This page is informational and not investment advice.